S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

STRO Sutro Biopharma Inc

1.9999

0.0999 (5.26%)

05 Feb 2025 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma Inc News

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Wednesday 8 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Wednesday 8 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 11 December 2024 (2 months ago) • Edgar (US Regulatory)

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Wednesday 11 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Thursday 14 November 2024 (3 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Tuesday 5 November 2024 (3 months ago) • GlobeNewswire Inc.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Friday 1 November 2024 (3 months ago) • GlobeNewswire Inc.

More Sutro Biopharma Inc News Articles

Commonwealth Bank Of Aus...

S&P ASX 300 Metals and M...

National Australia Bank

Woodside Petroleum

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions